Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company
15 Octobre 2013 - 11:05PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that
Morgan Stanley & Co. LLC and Credit Suisse Securities (USA)
LLC, the joint book-running managers in the Company's recent public
sale of 9,686,171 shares of common stock, are releasing a lock-up
restriction with respect to 95,962 shares of the Company's common
stock held by a director of the Company. The release will take
effect concurrently with the pricing of the proposed public
offering under a registration statement on Form S-1 initially filed
by the Company on October 7, 2013, for the purpose of allowing the
director to sell those shares in the proposed public offering.
This press release is not an offer for sale of the
securities in the United States or in any other jurisdiction where
such offer is prohibited, and such securities may not be offered or
sold in the United States absent registration or an exemption from
registration under the United States Securities Act of 1933, as
amended.
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur